Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L A Baxter

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Journal of Hematotherapy|January 27, 1999
Cord Blood Transplantation Study (COBLT): cord blood bank standard operating proceduresJ K Fraser, M S Cairo, E L Wagner, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 22, 2012
Beta-adrenergic receptor polymorphisms and cardiac graft function in potential organ donorsK K Khush, L Pawlikowska, R L Menza, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 7, 2012
The 4G/4G genotype of the PAI-1 (serpine-1) 4G/5G polymorphism is associated with decreased lung allograft utilizationA Sapru, J G Zaroff, L Pawlikowska, et al.
Bone Marrow Transplantation|September 7, 2010
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescentsJ Styczynski, B Tallamy, I Waxman, et al.
Bone Marrow Transplantation|May 7, 2014
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell diseaseM Bhatia, Z Jin, C Baker, et al.
Human Immunology|May 20, 2008
Strategies and technical challenges in allele level Class II typing in 2578 bone marrow transplantation donor-recipient pairsT M Williams, T Winden, M Setterholm, et al.
Tissue Antigens|January 1, 1996
Large-scale DRB and DQB1 oligonucleotide typing for the NMDP registry: progress report from year 2J Ng, C K Hurley, C Carter, et al.
Bone Marrow Transplantation|July 31, 2007
Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseasesM B Bradley, P Satwani, L Baldinger, et al.
Bone Marrow Transplantation|March 21, 2000
The extent of HLA class II allele level disparity in unrelated bone marrow transplantation: analysis of 1259 National Marrow Donor Program donor-recipient pairsC K Hurley, L A Baxter-Lowe, A B Begovich, et al.
Bone Marrow Transplantation|June 12, 2012
The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipientsJ B Le Gall, M C Milone, I M Waxman, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Journal of Hematotherapy|January 27, 1999
Cord Blood Transplantation Study (COBLT): cord blood bank standard operating proceduresJ K Fraser, M S Cairo, E L Wagner, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 22, 2012
Beta-adrenergic receptor polymorphisms and cardiac graft function in potential organ donorsK K Khush, L Pawlikowska, R L Menza, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 7, 2012
The 4G/4G genotype of the PAI-1 (serpine-1) 4G/5G polymorphism is associated with decreased lung allograft utilizationA Sapru, J G Zaroff, L Pawlikowska, et al.
Bone Marrow Transplantation|September 7, 2010
A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescentsJ Styczynski, B Tallamy, I Waxman, et al.
Bone Marrow Transplantation|May 7, 2014
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell diseaseM Bhatia, Z Jin, C Baker, et al.
Human Immunology|May 20, 2008
Strategies and technical challenges in allele level Class II typing in 2578 bone marrow transplantation donor-recipient pairsT M Williams, T Winden, M Setterholm, et al.
Tissue Antigens|January 1, 1996
Large-scale DRB and DQB1 oligonucleotide typing for the NMDP registry: progress report from year 2J Ng, C K Hurley, C Carter, et al.
Bone Marrow Transplantation|July 31, 2007
Reduced intensity allogeneic umbilical cord blood transplantation in children and adolescent recipients with malignant and non-malignant diseasesM B Bradley, P Satwani, L Baldinger, et al.
Bone Marrow Transplantation|March 21, 2000
The extent of HLA class II allele level disparity in unrelated bone marrow transplantation: analysis of 1259 National Marrow Donor Program donor-recipient pairsC K Hurley, L A Baxter-Lowe, A B Begovich, et al.
Bone Marrow Transplantation|June 12, 2012
The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipientsJ B Le Gall, M C Milone, I M Waxman, et al.
Pageof 9